95%of GISTs are KIT positive

The mutated KIT protein is a key driver of GIST.4

KIT (CD117) staining is used to confirm the diagnosis of KIT-positive (KIT+) GIST, and is the diagnostic marker for this cancer.5

Learn More
slide 1 slide 1 slide 1
95%of GISTs are KIT positive

Many patients with GIST may experience tumor recurrence at some point following tumor resection.1,7 Studies show that, historically, as many as one in two patients experiences GIST recurrence within 5 years of resection.1,6 When tumor recurrence is detected, GIST is considered to have metastasized.1

Learn More
slide 1 slide 1 slide 1
95%of GISTs are KIT positive

CAP has established a protocol for the standardized evaluation of GIST.8,9 In addition to a checklist and background information on GIST, the CAP protocol lists important differentiating features, tests, and prognostic factors.

Learn More
slide 1 slide 1 slide 1

Endoscopic Images of 4 Gastric SEMLs

endoscopic image

Images courtesy of Douglas O. Faigel,
MD, FACG, FASGE, AGAF

Can you identify the GIST?

A heterogeneous morphology has made GIST underrecognized and misdiagnosed.10

  • GISTs have been misidentified as other GI cancers or noncancerous conditions.11

SEMLs, subepithelial mass lesions.

 
Get the Answer
 
 
 
 
 

Learn from the leaders

Leaders

Follow diagnostic and management pathways through a series of specialty and case-based modules from experts in gastroenterology, pathology, and surgery.

 
Start Here
 
 
 
 

References:
1. Referenced with permission from the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ Soft Tissue Sarcoma (V.1.2011). Available at: http://www.nccn.org. ©National Comprehensive Cancer Network, Inc. 2011. To view the most recent and complete version of the NCCN Guidelines™, go online to www.nccn.org. 2. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259-1269. 3. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-465. 4. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007;369:1731-1741. 5. Joensuu H. Current perspectives on the epidemiology of gastrointestinal stromal tumours. Eur J Cancer Suppl. 2006;4(suppl 1):4-9. 6. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-58. 7. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813-3825. 8. Rubin BP, Blanke CD, Demetri GD, et al. Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Arch Pathol Lab Med. 2010;134:165-170. 9. College of American Pathologists Web site. http://www.cap.org. Accessed March 1, 2011. 10. Demetri GD. In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:1204-1217. 11. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466-1478.